114
Participants
Start Date
August 5, 2025
Primary Completion Date
November 30, 2026
Study Completion Date
December 31, 2028
Durvalumab
Durvalumab IV (intravenous infusion)
Tremelimumab
Tremelimumab IV (intravenous infusion)
Lenvatinib
Lenvatinib Oral
NOT_YET_RECRUITING
Research Site, Beijing
NOT_YET_RECRUITING
Research Site, Beijing
NOT_YET_RECRUITING
Research Site, Beijing
RECRUITING
Research Site, Shanghai
NOT_YET_RECRUITING
Research Site, Nanjing
NOT_YET_RECRUITING
Research Site, Nanjing
NOT_YET_RECRUITING
Research Site, Hefei
NOT_YET_RECRUITING
Research Site, Jinan
NOT_YET_RECRUITING
Research Site, Tianjin
NOT_YET_RECRUITING
Research Site, Hangzhou
NOT_YET_RECRUITING
Research Site, Ningbo
NOT_YET_RECRUITING
Research Site, Wenzhou
NOT_YET_RECRUITING
Research Site, Xiamen
NOT_YET_RECRUITING
Research Site, Chongqing
NOT_YET_RECRUITING
Research Site, Wuhan
NOT_YET_RECRUITING
Research Site, Zhengzhou
NOT_YET_RECRUITING
Research Site, Guangzhou
NOT_YET_RECRUITING
Research Site, Guangzhou
NOT_YET_RECRUITING
Research Site, Guangzhou
NOT_YET_RECRUITING
Research Site, Guangzhou
RECRUITING
Research Site, Chengdu
NOT_YET_RECRUITING
Research Site, Taiyuan
Lead Sponsor
AstraZeneca
INDUSTRY